Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.

C Mircea S Tesileanu Martin J Van Den BentMarc SansonWolfgang WickAlba A BrandesPaul M ClementSara C ErridgeMichael A VogelbaumAnna K NowakJean F BaurainWarren P MasonHelen WheelerOlivier L ChinotSanjeev GillMatthew GriffinLeland RogersWalter TaalRoberta RudàMichael WellerCatherine McBainMyra E van LindeThais S SabedotYouri HoogstrateAndreas von DeimlingIris de HeerWilfred F J van IJckenRutger W W BrouwerKenneth AldapeRobert B JenkinsHendrikus J DubbinkJohan M KrosPieter WesselingKin Jip CheungVassilis GolfinopoulosBrigitta G BaumertThierry GorliaHoutan NoushmehrPim J French

Published in: Neuro-oncology (2021)

Both clinical and molecular factors identify IDH1/2mt anaplastic astrocytoma patients with worse outcome. These results will further refine the current WHO criteria for glioma classification.

Keyphrases

dna methylation
genome wide
phase iii
phase ii
open label
double blind
clinical trial
gene expression
deep learning
machine learning
study protocol
placebo controlled
copy number
low grade
high grade
wild type